Most participants recruited for the MS analysis (Table S1a) were treatment naive or systemic treatment free; however, we were also interested to see if there was diagnostic potential for elafin and IL‐36γ in patients under active systemic treatments reflecting ‘real‐world’ settings. This evidence concerns the gene IL36G and myeloid sarcoma.